spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Betrixaban 

 HSMN NewsFeed - 14 May 2020
U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa(R) for Third Year
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 7 Apr 2020
Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 5 Mar 2020
New Data Demonstrates Andexxa(R) Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors
Biopharmaceuticals
 HSMN NewsFeed - 3 Feb 2020
Portola Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Mar 2018
Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Nov 2016
Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban
Biopharmaceuticals
 HSMN NewsFeed - 30 Aug 2016
Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXXA-4(TM) Study of Factor Xa Inhibitor Antidote AndexXa(TM) (andexanet alfa) in Patients with Acute Major Bleeding
Biopharmaceuticals
 HSMN NewsFeed - 26 Aug 2016
Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA(TM)-4 Study of AndexXa(TM) (andexanet alfa) at European Society of Cardiology 2016 Congress
Biopharmaceuticals
 HSMN NewsFeed - 19 Aug 2016
Portola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa(TM) (andexanet alfa), a Factor Xa Inhibitor Antidote
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 May 2016
Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
Biopharmaceuticals
 HSMN NewsFeed - 18 Mar 2014
Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jan 2014
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis
Biopharmaceuticals
 HSMN NewsFeed - 12 Apr 2011
Portola Pharmaceuticals Appoints Dr. James Topper to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Sep 2010
Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Mar 2010
Portola Pharmaceuticals Announces Senior Management and Board Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Sep 2009
Portola Pharmaceuticals Announces Promotions of Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jul 2009
Merck & Co., Inc. and Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban, a Novel Investigational Oral Anticoagulant for Cardiovascular Disease
Biopharmaceuticals Licensing
 HSMN NewsFeed - 9 Dec 2008
Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 9 Jul 2008
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Jun 2008
Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
Biopharmaceuticals Personnel
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.